Repligen Corporation http://www.alacrastore.com/company-snapshot/Repligen_Corporation-1014072 Friday, October 10, 2008 10:55:52 PM 1014072 Repligen Corporation en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/PRN-0005-28116323newstex/PRN-0005-28116323xml WALTHAM, Mass., Sep. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the ####...070000000700500004000000040020000400200604016000040160279/17/2008 10:22:21 AM1800000018014000PR Newswire USPRN-0005-28116323REPLIGEN CORPUBS AGWALTER C HERLIHYRGENUBSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-28095585newstex/PRN-0005-28095585xml WALTHAM, Mass., Sep. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Repligen Corporation (Nasdaq: RGEN) today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved...0700000007001000070050000400000004002000040020060401600004016027130000001301000013010005130020001300200507014000070140121100000011016000110160010200000002002000020020069/16/2008 12:22:15 PM18000000180180001801400018020000190000001900100019001032PR Newswire USPRN-0005-28095585REPLIGEN CORPWALTER C HERLIHYRGENNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27882032newstex/PRN-0005-27882032xml WALTHAM, Mass., Sep. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $#.### million in research grants to support the development of new treatments...0700000007005000040000000400200004002006040160000401602707014000070140121300000013010000130100050200000002002000020020069/4/2008 8:23:47 AM180000001802000018014000PR Newswire USPRN-0005-27882032REPLIGEN CORPWALTER C HERLIHYRGENNewsNewstexhttp://www.alacrastore.com/storecontent/bir/321902bir/321902normRepligen Corp.United StatesManufacturing: Therapeutics for the treatment of profound neuropsychiatric disorders, with particular emphasis on applications for children.28363254142417BERGEN8/26/2008 6:21:42 AM321902Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/ccbn/T1913723ccbn/T1913723norm...Good day, and welcome to the first quarter Repligen Corporation earnings conference call. My name is Brandi, and I'll be your operator for today. (Operator Instructions). I would like to turn the call over to Mr. Bill Kelly, Vice President of Finance and Administration. Please proceed, sir. ... 8/7/2008 2:07:00 PMRepligen Corporation54.0000FinalRepligen Corporation Q1 2009 Earnings Conference Call TranscriptRGEN11:00am ETTranscriptT1913723Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27236145newstex/PRN-0005-27236145xml WALTHAM, Mass., Aug. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Repligen Corporation (Nasdaq: RGEN) today reported results for the first quarter of fiscal year ####, ended June ##, ####. Total revenue for the quarter was...07000000070050000400000004002000040020060401600004016048040160010401601804016003040160270701400007014013070140120701401107003000070030040200000002002000020020081300000013010000130100058/7/2008 9:27:20 AM18000000180080001800400018018000180200001900000019001000PR Newswire USPRN-0005-27236145REPLIGEN CORPWALTER C HERLIHYRGENNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-27071752newstex/PRN-0005-27071752xml WALTHAM, Mass., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference...070000000700500004000000040020000400200604016000040160480401601804016001040160277/31/2008 11:23:41 AM180000001800800018004000PR Newswire USPRN-0005-27071752REPLIGEN CORPTHOMSONWALTER C HERLIHYRGENTMSNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1816210ccbn/T1816210norm...Good day, ladies and gentlemen, and welcome to the Repligen Corporation for an update on the Orencia lawsuit. (OPERATOR INSTRUCTIONS). I will now turn the call over to Mr. Walter Herlihy. Please proceed. ... 7/16/2008 4:55:31 PMRepligen Corporation54.0000Repligen Corporation Conference Call to Provide an Update on the Orencia« LawsuitRGEN9:00AM ETTranscriptT1816210Credit & Investment ResearchThomson StreetEventsUS - In June ####, the board of Repligen Corp (RC), a biopharmaceutical company, authorized the repurchase of up to #.## mil common shares, or about #% of the company's common stock outstanding, in open market or privately negotiated transactions. Based on RC's closing stock price of $#.## on June ##, the last full trading day prior to the announcement of the board's approval, the buyback had an indicated value of up to $#.### mil.6/19/2008 5:24:21 PM759916759916759916759916Repligen CorpRepligen CorpRepligen CorpRepligen Corphttp://www.alacrastore.com/storecontent/Thomson_M%26A/Repligen_Corp_buys_back_stock-1988166020sdc/19881660201988166020Copyright © 2008, Thomson Financial, All Rights ReservedNasdaqDrugsUnited StatesBiological products, except diagnostic substances2836MAMassachusettsPublicRGEN2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizationsNasdaqDrugsUnited StatesBiological products, except diagnostic substances2836MAMassachusettsPublicRGEN5073001Biopharmaceutical coBiopharmaceutical coCashCash OnlyCommon Stock5073001Jun 19 20080.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.00000Repligen Corp, located inWaltham, Massachusetts, is abiopharmaceutical company,engages in the research anddevelopment of therapeuticsfor the treatment of centralnervous system diseases. Thecompany manufactures anddevelops Protein A product,which is used in theproduction of varioustherapeutic monoclonalantibodies. It was founded in1981.Repligen Corp, located in Waltham, Massachusetts, is abiopharmaceutical company, engages in the research anddevelopment of therapeutics for the treatment of centralnervous system diseases. The company manufactures anddevelops Protein A product, which is used in the productionof various therapeutic monoclonal antibodies. It was foundedin 1981.Repligen Corp, located in Waltham, Massachusetts, is a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases. The company manufactures and develops Protein A product, which is used in the production of various therapeutic monoclonal antibodies. It was founded in 1981.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.00000Repligen Corp, located inWaltham, Massachusetts, is abiopharmaceutical company,engages in the research anddevelopment of therapeuticsfor the treatment of centralnervous system diseases. Thecompany manufactures anddevelops Protein A product,which is used in theproduction of varioustherapeutic monoclonalantibodies. It was founded in1981.Repligen Corp, located in Waltham, Massachusetts, is abiopharmaceutical company, engages in the research anddevelopment of therapeutics for the treatment of centralnervous system diseases. The company manufactures anddevelops Protein A product, which is used in the productionof various therapeutic monoclonal antibodies. It was foundedin 1981.Repligen Corp, located in Waltham, Massachusetts, is a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases. The company manufactures and develops Protein A product, which is used in the production of various therapeutic monoclonal antibodies. It was founded in 1981.0.000000.000000.0000031.17000NU.S. Dollar18 Jun 08Wed, 18 Jun 2008 00:00:00 ESTDate Announced: 06/18/2008Date Effective:BuybackNot Appl.0.000000.000000.000000.000000.000004.75000Price/Share0.000005.938 U.S. Dollar5.93800148.068005.938 U.S. Dollar5.938000.000000.000004.750004.750005.938005.938 U.S. Dollar1.00000N3.032000.000000.000000.000000.000000.000005.938005.938000.000000.000000.000000.000000.000000.000000.000004.010000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.0000015.0000016.00000US - In June 2008, the boardof Repligen Corp (RC), abiopharmaceutical company,authorized the repurchase ofup to 1.25 mil common shares,or about 4% of the company'scommon stock outstanding, inopen market or privatelynegotiated transactions. Basedon RC's closing stock price of$4.75 on June 17, the lastfull trading day prior to theannouncement of the board'sapproval, the buyback had anindicated value of up to$5.938 mil.US - In June 2008, the board of Repligen Corp (RC), a biopharmaceutical company, authorized the repurchase of up to 1.25 mil common shares, or about 4% of the company's common stock outstanding, in open market or privately negotiated transactions. Based on RC's closing stock price of $4.75 on June 17, the last full trading day prior to the announcement of the board's approval, the buyback had an indicated value of up to $5.938 mil.US - In June 2008, the board of Repligen Corp (RC), a biopharmaceutical company,authorized the repurchase of up to 1.25 mil common shares, or about 4% of the company'scommon stock outstanding, in open market or privately negotiated transactions. Based onRC's closing stock price of $4.75 on June 17, the last full trading day prior to theannouncement of the board's approval, the buyback had an indicated value of up to $5.938mil.US - In June 2008, the board of Repligen Corp (RC), a biopharmaceutical company, authorized the repurchase of up to 1.25 mil common shares, or about 4% of the company's common stock outstanding, inopen market or privately negotiated transactions. Based on RC's closing stock price of $4.75 on June 17, the last full trading day prior to the announcement of the board's approval, the buyback had anindicated value of up to $5.938 mil.US - In June 2008, the board of Repligen Corp (RC), a biopharmaceutical company, authorized the repurchase of up to 1.25 mil commonshares, or about 4% of the company's common stock outstanding, in open market or privately negotiated transactions. Based on RC's closingstock price of $4.75 on June 17, the last full trading day prior to the announcement of the board's approval, the buyback had anindicated value of up to $5.938 mil.Intended0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Intended-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations5073001NasdaqUnited States2836MassachusettsPublicRGEN2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations5073001NasdaqUnited States2836MassachusettsPublicRGEN5.938005.938005.938003.03200Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/T1871816ccbn/T1871816norm...Good day ladies and gentlemen and welcome to the fourth quarter #### Repligen Corporation earnings conference call. My name is Dan and I'll be your coordinator for today. At this time, all participants are in a listen-only mode. (OPERATOR INSTRUCTIONS). I would now like to turn the call over to your host for today's call, Mr. Bill Kelly, Vice President of Finance and Administration. Please proceed, sir. ... 6/12/2008 12:04:00 PMRepligen Corporation54.0000FinalQ4 2008 Repligen Corporation Earnings Conference Call TranscriptRGEN11:00am ETTranscriptT1871816Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1746229ccbn/T1746229normQ# #### Repligen Corporation Earnings Conference Call2/7/2008 12:07:00 PMRepligen Corporation54.0000FinalQ3 2008 Repligen Corporation Earnings Conference Call TranscriptRGEN11:00am ETTranscriptT1746229Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1676022ccbn/T1676022norm11/8/2007 9:07:00 PMRepligen Corporation54.0000FinalQ2 2008 Repligen Corporation Earnings Conference Call TranscriptRGEN11:00am ET...Good day, ladies and gentlemen, and welcome to the Second Quarter #### Repligen Corporation Earnings Conference Call. My name is Tawanda and I will be your coordinator for today. (OPERATOR INSTRUCTIONS.) I would now like to turn the call over to Mr. Walter Herlihy, President and CEO. Please proceed, sir. ... TranscriptT1676022Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/25753srp/25753norm...Address:## Seyon Street Building ##, Suite ###, Waltham, Massachusetts ##### Incorporated:DelawareWeb Site: www.repligen.comSIC Classification: Biological Products, Except Diagnostic Substances (####) Business Description: Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of new products for profound pediatric developmental disorders. Indices:Russell ####, Russell #### ... 25753759916109RGEN10/6/2006 12:38:00 PM25753Credit & Investment ResearchSharkRepellent.net